Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, today announced that data from five studies will be highlighted in two oral presentations and three poster sessions at the American Society of Gene & Cell Therapy 22nd Annual Meeting, taking place between 29 April and 2 May in Washington, DC, USA.
Oxford, UK – 30 April 2019: Oxford BioMedica PLC(LSE:OXB), a leading gene and cell therapy group, today announced that data from five studies will be highlighted in two oral presentations and three poster sessions at the American Society of Gene & Cell Therapy 22nd Annual Meeting, taking place between 29 April and 2 May in Washington, DC, USA.
An oral presentation by OXB will highlight previously published preclinical data from an investigation of 5T4 expression and the potential of a CAR-T therapy, OXB-302, as a treatment for haematological and solid tissue cancers. In a separate oral presentation, details from the ongoing SUNRISE-PD Phase 1/2 trial of AXO-Lenti-PD for the treatment of Parkinson’s disease will be shared by OXB’s partner, Axovant Gene Therapies.
Additional poster presentations by OXB scientists will highlight preclinical data on OXB-203, OXB’s programme for wet age-related macular degeneration, as well as presentations on OXB’s LentiVector® manufacturing process.
Dr Kyriacos Mitrophanous, Chief Scientific Officer of Oxford Biomedica, said:
“Our scientific presence at ASGCT demonstrates the strength of our LentiVector® platform. We look forward to highlighting the potential of gene and cell therapy with lentiviral vectors, both in our own proprietary programmes and in those of our partners, to further advance our mission to deliver life-changing therapies to patients.”
Oral presentations:
Title: Pre-Clinical Investigations of CAR T Cells Directed Against the Tumour Antigen 5T4 (OXB-302) in Solid Tumor Models (Abstract #373)
Session: Immunotherapy 1
Date and time: Tuesday, 30 April 2019, 9.45-10am ET
Note: includes new data as well as data previously presented at the International Symposium on Immunotherapy, 12-13 May 2017 and published in the Journal of Immunotherapy*
Title: AXO-Lenti-PD: A Second-Generation Lentiviral Gene Therapy for the Treatment of Parkinson’s Disease (Abstract #222)
Session: Gene replacement for neurological diseases
Date and time: Tuesday, 30 April 2019, 3.30-3.45pm ET
Poster presentations:
Title: Highly Efficient Clearance of Residual DNA During Viral Vector Biogenesis Using Co-Expressed Secreted Nucleases (Abstract #443)
Session: Poster Session II: RNA Virus vectors
Date and time: Tuesday, 30 April, 5.00-6.00pm ET
Title: OXB-203, a Lentiviral Vector Expressing Aflibercept as a Single Dose, Long-Term Treatment for Wet Age-Related Macular Degeneration (Abstract #544)
Session: Poster Session II: Neurologic Diseases
Date and time: Tuesday 30 April 2019 5.00-6:00pm ET
Title: GMP Manufacturing of Lentiviral Vectors: Scale-Up Considerations (Abstract #893)
Session: Poster session III: Vector and cell engineering, production or manufacturing II
Date and time: Wednesday, 1 May 5.00-6.00pm ET
*DOI: 10.1097/ CJI.0000000000000203
-Ends-
| Enquiries: | |
| Oxford Biomedica plc John Dawson, Chief Executive Officer Stuart Paynter, Chief Financial Officer Catherine Isted, Head of Corporate Development & IR Sarah MacLeod, Head of Communications | T: +44 (0)1865 783 000 T: +44 (0)1865 783 000 T: +44 (0)1865 954 161 / E: ir@oxb.com T: +44 (0)7747 602 739 / E: media@oxb.com |
| Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal | T: +44 (0)20 3709 5700 |
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the “Group”) have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 430 people. For more information, visit www.oxb.com
